<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neth Heart J</journal-id><journal-id journal-id-type="iso-abbrev">Neth Heart J</journal-id><journal-title-group><journal-title>Netherlands Heart Journal</journal-title></journal-title-group><issn pub-type="ppub">1568-5888</issn><issn pub-type="epub">1876-6250</issn><publisher><publisher-name>Bohn Stafleu van Loghum</publisher-name><publisher-loc>Houten</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6439041</article-id><article-id pub-id-type="publisher-id">1241</article-id><article-id pub-id-type="doi">10.1007/s12471-019-1241-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article &#8211; Design Study Article</subject></subj-group></article-categories><title-group><article-title>A&#160;randomised, investigator-initiated, clinical trial of the effects of fentanyl on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: rationale and design of the Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME&#160;3) trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tavenier</surname><given-names>A. H.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hermanides</surname><given-names>R. S.</given-names></name><address><email>r.s.hermanides@isala.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ottervanger</surname><given-names>J. P.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rasoul</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Slingerland</surname><given-names>R. J.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Tolsma</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>van Workum</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kedhi</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>van &#8217;t Hof</surname><given-names>A. W. J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0547 5927</institution-id><institution-id institution-id-type="GRID">grid.452600.5</institution-id><institution>Department of Cardiology, </institution><institution>Isala, </institution></institution-wrap>Zwolle, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0480 1382</institution-id><institution-id institution-id-type="GRID">grid.412966.e</institution-id><institution>Department of Cardiology, </institution><institution>Maastricht University Medical Centre, </institution></institution-wrap>Maastricht, The Netherlands </aff><aff id="Aff3"><label>3</label>Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0547 5927</institution-id><institution-id institution-id-type="GRID">grid.452600.5</institution-id><institution>Department of Clinical Chemistry, </institution><institution>Isala, </institution></institution-wrap>Zwolle, The Netherlands </aff><aff id="Aff5"><label>5</label>RAV IJsselland, Zwolle, The Netherlands </aff><aff id="Aff6"><label>6</label>RAV Zuid-Limburg, Heerlen, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>2</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>2</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2019</year></pub-date><volume>27</volume><issue>4</issue><fpage>185</fpage><lpage>190</lpage><permissions><copyright-statement>&#169; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Fast and accurate platelet inhibition is an important therapeutic goal in the acute treatment of patients with ST-elevation myocardial infarction (STEMI). Platelet inhibitory effects induced by oral P2Y12-receptor antagonists are delayed in STEMI patients undergoing primary percutaneous coronary intervention (PCI) due to haemodynamic changes and delayed gastro-intestinal absorption. Concomitant use of opioids, although recommended in the American College of Cardiology/American Heart Association and European Society of Cardiology STEMI guidelines, further delays gastro-intestinal absorption. To date, trials investigating alternative analgesics in STEMI patients have been scarce. This trial aims to assess the feasibility of a&#160;novel drug strategy for treatment of STEMI patients with crushed ticagrelor in combination with paracetamol (acetaminophen) instead of opioids.</p></sec><sec><title>Hypothesis</title><p>STEMI patients who are pre-treated with crushed ticagrelor and paracetamol have a&#160;higher level of platelet inhibition after primary PCI than patients pre-treated with crushed ticagrelor and fentanyl.</p></sec><sec><title>Study design</title><p>The Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME&#160;3) trial is a&#160;randomised controlled trial designed to examine whether administration of paracetamol instead of fentanyl can optimise platelet inhibition in STEMI patients who are pre-treated with crushed ticagrelor in the ambulance. One hundred and ninety patients with STEMI will be randomised (1:1&#160;fashion) to intravenous (IV) fentanyl or IV paracetamol. The primary endpoint is the level of platelet reactivity units measured immediately after primary PCI.</p></sec><sec><title>Summary</title><p>The ON-TIME&#160;3 trial (NCT03400267) aims to achieve optimal platelet inhibition and pain relief in STEMI patients receiving crushed ticagrelor in the ambulance by investigating IV&#160;fentanyl and IV&#160;paracetamol as analgesics.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>ST-elevation myocardial infarction</kwd><kwd>Ticagrelor</kwd><kwd>Platelet inhibition</kwd><kwd>Primary percutaneous coronary intervention</kwd><kwd>Fentanyl</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Adequate and optimal platelet inhibition is an important therapeutic goal in the treatment of patients with ST-elevation myocardial infarction (STEMI). Platelet inhibitory effects induced by potent oral P2Y12-receptor antagonists like ticagrelor are delayed in STEMI patients undergoing primary percutaneous coronary intervention (PCI) [<xref ref-type="bibr" rid="CR1">1</xref>]. STEMI-induced selective shunting of blood to vital organs decreases gastro-intestinal perfusion and induces impaired drug absorption. Furthermore, analgesic drugs such as fentanyl and morphine, which are recommended according to American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology (ESC) STEMI guidelines [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], are used in STEMI to reduce pain-associated sympathetic activation, which increases vasoconstriction, blood pressure and heart rate [<xref ref-type="bibr" rid="CR4">4</xref>]. In addition, the uptake of P2Y12&#160;inhibitors can be further delayed by drug interactions. In particular, morphine delays the intestinal drug absorption of P2Y12&#160;inhibitors [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>In the past, different trials have investigated the influence of morphine on platelet inhibition. The IMPRESSION trial [<xref ref-type="bibr" rid="CR5">5</xref>] found that administration of morphine in patients with STEMI and non-STEMI influenced the pharmacokinetics by lowering the total exposure to in-hospital-administered ticagrelor and its active metabolite by 36% and 37%, respectively, and delayed the time to maximal plasma concentration of ticagrelor. Also, the effects of morphine on pharmacodynamics have been described and, more frequently, a&#160;high platelet reactivity was observed in STEMI patients treated with a&#160;P2Y12&#160;inhibitor and receiving morphine [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], which is a&#160;phenomenon known to be associated with acute stent thrombosis [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. The PACIFY trial [<xref ref-type="bibr" rid="CR9">9</xref>] investigated the influence of fentanyl, a&#160;potent opioid, on platelet inhibition and showed lower plasma concentrations of ticagrelor and delayed antiplatelet effects in patients receiving fentanyl during elective angiography.</p><p>Different studies have shown that morphine may have adverse effects on inhibitory properties of antiplatelet agents [<xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>], myocardial reperfusion [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], and also on all-cause mortality in patients with acute myocardial infarction [<xref ref-type="bibr" rid="CR15">15</xref>]. However, reports from other studies failed to show such an association [<xref ref-type="bibr" rid="CR16">16</xref>]. Finally, the pain-relieving effects of morphine in STEMI patients have not been fully investigated yet. To date, trials investigating alternative analgesics in STEMI patients have been scarce.</p><p>Different routes of administration of P2Y12&#160;inhibitors like ticagrelor in STEMI patients have been investigated to improve gastro-intestinal absorption. The MOJITO study [<xref ref-type="bibr" rid="CR17">17</xref>] randomised patients with STEMI undergoing primary PCI into crushed or integral tablets of ticagrelor. Crushed ticagrelor tablet administration in STEMI patients was feasible and provided earlier platelet inhibition compared with standard integral tablets. However, sublingual crushed administration of ticagrelor did not further improve the uptake in patients with unstable angina [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>The Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME&#160;3) trial aims to study the impact of an alternative non-opioid analgesic, paracetamol (acetaminophen), as compared to fentanyl in combination with crushed ticagrelor administration in the ambulance on platelet inhibition in STEMI patients.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and objective</title><p>The ON-TIME&#160;3 trial is a&#160;prospective, randomised trial, of which the primary objective is to assess the level of platelet inhibition after primary PCI in STEMI patients who are pre-treated with crushed ticagrelor and paracetamol compared to patients who are pre-treated with crushed ticagrelor and fentanyl. The study will be performed in two hospitals: Isala Hospital in Zwolle and Zuyderland Medical Centre in Heerlen. All study drugs are administered in the ambulance.</p></sec><sec id="Sec4"><title>Trial registration</title><p>This study will be conducted in accordance with the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013), the Medicinal Research Involving Human Subjects Act (WMO) and ICH-Good Clinical Practice (GCP). The study protocol and patient informed consent are approved by the local ethics committee. The ON-TIME&#160;3 trial is registered on ClinicalTrials.gov (NCT03400267).</p></sec><sec id="Sec5"><title>Study protocol, randomisation and follow-up</title><p>All STEMI patients (defined as on-going chest pain&#8239;&gt;&#8201;30&#8239;min and &lt;12&#8239;h duration and ST-segment elevation&#8239;&gt;&#8201;0.1&#8239;mV in at least two contiguous leads) as diagnosed by the paramedic team on arrival at the patient site that comply with the inclusion and exclusion criteria (Tab.&#160;<xref rid="Tab1" ref-type="table">1</xref>) will be asked to participate in this trial. After verbal informed consent patients will be randomised in a&#160;1:1 fashion to either intravenous (IV) fentanyl or IV&#160;paracetamol (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The trial is not blinded. All patients will be pre-loaded in the ambulance with unfractionated heparin 5,000&#160;IU and aspirin 500&#8239;mg IV according to standard care and 180&#8239;mg crushed oral ticagrelor. The paramedic team will register vital parameters and pain scores on a&#160;10-step pain scale. Descriptive statistics will be derived from electronic medical clinical records and stored in an electronic case report form (eCRF). Haemodynamic parameters and data on intensity of pain will be collected in the ambulance at initial presentation. Data on intensity of pain and data on platelet inhibition, including pharmacokinetics and pharmacodynamics, will be collected before (T1) and immediately after primary PCI (T2) at the catheterisation laboratory, 1&#8239;h (T3), 3 and 6&#8239;h (T4) post-primary PCI at the coronary care unit. A&#160;30-day post-randomisation follow-up will be performed by telephone interview (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Pharmacokinetics will be evaluated using appropriate pharmacokinetics modelling software (e.&#8239;g. NONNEM or MWPharm) by determination of the concentration of ticagrelor and its active metabolite, AR-C124910XX, using liquid chromatography-mass spectrometry in the clinical chemistry laboratory in Zwolle. Pharmacodynamics will be assessed by a&#160;VerifyNow point of care test that measures the platelet reactivity units (PRU). Patients will be treated during hospital admission according to current ACC/AHA and ESC STEMI guidelines [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Written informed consent will be obtained during hospital admission.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inclusion and exclusion criteria</p></caption><table-wrap-foot><p><italic>STEMI</italic>&#160;ST-elevation myocardial infarction</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Schematic chart of ON-TIME&#160;3 trial with randomisation and time of measurements (<italic>T1</italic>&#160;arrival at cath lab, <italic>T2</italic>&#160;end of primary PCI, <italic>T3</italic>&#160;1&#8239;h post-primary PCI, <italic>T4</italic>&#160;6&#8239;h post-primary PCI). <italic>STEMI</italic>&#160;ST-elevation myocardial infarction, <italic>Primary PCI</italic>&#160;primary percutaneous coronary intervention</p></caption><graphic xlink:href="12471_2019_1241_Fig1_HTML" id="d29e541"/></fig></p></sec><sec id="Sec6"><title>Endpoints</title><sec id="Sec7"><title>Primary endpoint</title><p>The primary endpoint of the study is the level of PRU measured immediately post-primary PCI or 1&#8239;h post-angiography (Tab.&#160;<xref rid="Tab2" ref-type="table">2</xref>). Blood will be obtained for our primary endpoint just before sheath removal (T2).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Primary, secondary and exploratory endpoints</p></caption><table-wrap-foot><p><italic>ARC</italic>&#160;Academic Research Consortium, <italic>BARC</italic>&#160;Bleeding Academic Research Consortium, <italic>CABG</italic> coronary artery bypass grafting, <italic>MACE</italic>&#160;major adverse cardiac events, <italic>PCI</italic>&#160;percutaneous coronary intervention, <italic>PRU</italic>&#160;platelet reactivity units, <italic>T1</italic>&#160;arrival at cath lab, <italic>T2</italic>&#160;end of primary PCI, <italic>T3</italic>&#160;1&#8239;h post-primary PCI, <italic>T4</italic>&#160;6&#8239;h post-primary PCI, <italic>TIMI</italic>&#160;thrombolysis in myocardial infarction</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>Secondary endpoints</title><p>The secondary endpoints (Tab.&#160;<xref rid="Tab2" ref-type="table">2</xref>) consist of the pain reduction on a&#160;10-step pain scale immediately post-primary PCI, the level of PRU at other time points, high on platelet reactivity (HPR) defined as PRU&#8239;&gt;&#8201;208&#8239;at all time points, the area under the curve of the concentrations of ticagrelor and its active metabolite at all time points, and thrombolysis in myocardial infarction (TIMI) 3 flow in the culprit vessel after primary PCI. Exploratory safety endpoints are major adverse cardiac events, defined as cardiac death, non-fatal re-myocardial infarction or target vessel revascularisation, stent thrombosis (ARC criteria [<xref ref-type="bibr" rid="CR19">19</xref>]), myocardial infarction after PCI [<xref ref-type="bibr" rid="CR20">20</xref>], non-coronary-artery-bypass-grafting (CABG)-related major bleeding (BARC&#160;3 and 5&#160;criteria [<xref ref-type="bibr" rid="CR21">21</xref>]) and all-cause mortality at 30&#160;days of follow-up.</p></sec></sec><sec id="Sec9"><title>Study drugs</title><p>Crushed ticagrelor (180&#8239;mg) will be prepared by using a&#160;crusher cup (Livsane), which allows preparation of crushed ticagrelor in an average time of 1&#8211;2&#8239;min. After 2&#160;times 5&#160;rotations of the crushing mechanism, the crushed pill contents will be mixed with 25&#8239;ml of H<sub>2</sub>O for 30&#8239;s in a&#160;150-ml dosing cup. The syringe crusher will be rinsed using an additional 25&#8239;ml of H<sub>2</sub>O and will be added to the dosing cup for a&#160;total of 50&#8239;ml suspension, which will be administered orally. When vomiting occurs and ticagrelor has been spit out, the patient will receive another loading dose of ticagrelor at the catheterisation laboratory. Paracetamol and fentanyl will be intravenously administered. Paracetamol 10&#8239;mg/ml is available in ampules of 100&#8239;ml (1000&#8239;mg) and its infusion time is 15&#8239;min. Fentanyl 50&#8239;&#181;g/ml is available in 2&#8239;ml ampules (100&#8239;&#181;g) and will be titrated based on the weight of the patient. Its infusion time is 30&#8239;s. The inhibitory pharmacodynamic or pharmacokinetic effects of paracetamol on platelet inhibition have not yet been described in the literature [<xref ref-type="bibr" rid="CR22">22</xref>&#8211;<xref ref-type="bibr" rid="CR24">24</xref>]. The use of all other intracoronary medication (heparin, nitroglycerin, adenosine and verapamil), the procedural technique at coronary angiography and the type of drug-eluting stent will be at the discretion of the operator. Administration of glycoprotein IIb/IIIa-receptor inhibitors will be restricted to bail-out situations only.</p></sec><sec id="Sec10"><title>Pre-specified subgroups for analysis</title><p>If a&#160;patient randomised to the paracetamol arm experiences unbearable pain (score&#8239;&gt;&#8201;8 on a&#160;10-step pain scale), bail-out medication like fentanyl 50&#8239;&#181;g (1&#8239;ml) can be given. Patients with bail-out use of fentanyl will be registered and analysed as a&#160;subgroup. Also patients with vomiting will be analysed as a&#160;subgroup.</p></sec><sec id="Sec11"><title>Statistical considerations</title><p>This trial is powered for the primary endpoint. Analyses will be performed for both the intention-to-treat and per-protocol population. The primary endpoint will be based on an intention-to-treat analysis.</p><sec id="Sec12"><title>Data analysis</title><p>Continuous variables in both study arms will be compared using a&#160;Student&#8217;s t&#8209;test or Mann-Whitney U&#160;test depending on the presence or absence of a&#160;normal distribution of the data as assessed by the Kolmogorov-Smirnov test. Proportions will be compared by the Chi-square test or a&#160;Fisher&#8217;s exact test when appropriate. Exploratory endpoints may be underpowered, and hence graphical methods and estimates with 95% confidence intervals will be used for evaluation. An interim analysis at 50% of inclusions is planned to monitor efficacy and safety during study enrolment.</p></sec><sec id="Sec13"><title>Sample size calculation</title><p>The ON-TIME&#160;3 is a&#160;superiority trial assessing the use of IV&#160;paracetamol compared to IV&#160;fentanyl in STEMI patients. Since the effects of paracetamol on PRU are not known yet and no identical studies have been performed, an assumption of the sample size was necessary. We partly based our sample size calculation on data of the IMPRESSION trial [<xref ref-type="bibr" rid="CR5">5</xref>] and PACIFY trial [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Assuming a&#160;60 PRU mean difference immediately after primary PCI between the two arms after a&#160;pre-hospital crushed ticagrelor loading dose with a&#160;standard deviation of 120 PRU, and 10% rate of invalid results due to haemolysis or technical problems, we estimate that 190 patients (95 per arm) will be needed to obtain a&#160;90% power and two-sided alpha of 0.05.</p></sec></sec><sec id="Sec14"><title>Expected results</title><p>The ON-TIME&#160;3 trial will be performed to show that STEMI patients treated pre-hospital with crushed ticagrelor and paracetamol have a&#160;higher level of platelet inhibition immediately after primary PCI than STEMI patients treated with crushed ticagrelor and fentanyl. The results of this trial have potential implications for the pre-hospital treatment of STEMI patients in the future.</p></sec></sec><sec id="Sec15"><title>Discussion</title><p>The absorption of more potent P2Y12&#160;platelet inhibitors (ticagrelor and prasugrel) is delayed in STEMI patients due to a&#160;reduced gastric perfusion and impaired gastric emptying [<xref ref-type="bibr" rid="CR1">1</xref>]. Opioids have widely been used in daily practice in STEMI patients and are recommended in international guidelines [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], but opioids also seem to impair gastro-intestinal absorption by reducing gut motility and can further delay the onset of the effect of platelet inhibitors [<xref ref-type="bibr" rid="CR5">5</xref>]. Moreover, nausea and vomiting are more often seen in patients receiving opioids [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], which reduce the uptake of platelet inhibitors. Therefore, a&#160;non-opioid analgesic like paracetamol (acetaminophen) may be beneficial in this respect.</p><p>Before effective platelet inhibition is reached, time passes and a&#160;gap of sub-optimal platelet inhibition exists, which is an important predictor of ischaemic complications, such as stent thrombosis [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. To accelerate and improve the absorption of platelet inhibitors several possibilities have been investigated, like pre-hospital administration of oral platelet inhibitors, crushed or chewed ticagrelor and IV&#160;administration of platelet inhibitors [<xref ref-type="bibr" rid="CR26">26</xref>&#8211;<xref ref-type="bibr" rid="CR28">28</xref>]. Administration of crushed ticagrelor has been shown to reduce the time to effective platelet inhibition in STEMI patients compared with standard integral tablets [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Other analgesics might be an alternative for opioid use in STEMI patients. While non-steroidal anti-inflammatory drugs are known to increase cardiovascular events [<xref ref-type="bibr" rid="CR29">29</xref>], paracetamol might be a&#160;suitable well-known alternative. IV&#160;administered paracetamol is effective more quickly than its oral form. Just a&#160;few clinically relevant side effects are known. The main side effect is hypotension when administered intravenously [<xref ref-type="bibr" rid="CR30">30</xref>]. However, gastro-intestinal side effects of paracetamol are less clear.</p><p>The ON-TIME&#160;3 trial continues to search for pain relief and fast and optimal platelet inhibition by investigating an alternative analgesic, paracetamol&#160;IV, in STEMI patients that all received crushed ticagrelor in a&#160;pre-hospital setting. The results of this trial have potential implications for the pre-hospital treatment of STEMI patients in the future and may change ambulance guidelines.</p><sec id="Sec16"><title>Limitations</title><p>Although we carefully designed our study, some limitations are present. Firstly, the investigated treatment group is a&#160;paracetamol arm instead of a&#160;placebo arm. IV&#160;paracetamol and IV&#160;fentanyl are administered in different ways. Therefore, blinding for randomisation to IV&#160;paracetamol and IV&#160;fentanyl was not possible. Secondly, since the primary endpoint is the PRU value immediately after primary PCI, the number of patients in this trial is too small to test our hypothesis on clinical outcomes. Moreover, the follow-up period of this trial is only a&#160;month after randomisation and therefore long-term outcome and conclusions cannot be drawn based on this research, although optimal antiplatelet therapy in the first hours of onset of STEMI and treatment with primary PCI is thought to be essential for long-term outcomes.</p></sec></sec><sec id="Sec17"><title>Summary</title><p>The ON-TIME&#160;3 trial is a&#160;prospective randomised trial which aims to assess whether STEMI patients who are treated pre-hospital with crushed ticagrelor and IV&#160;paracetamol have a&#160;higher level of platelet inhibition after primary PCI than patients treated with crushed ticagrelor and IV&#160;fentanyl.</p></sec></body><back><ack><sec id="FPar1"><title>Funding</title><p>The study will be conducted with an unrestricted grant of AstraZeneca and an unrestricted grant of the Isala Academy. AstraZeneca and the Isala Academy reviewed the study protocol during its development and were allowed to make suggestions, but the final content was determined by the authors.</p></sec></ack><notes notes-type="COI-statement"><sec id="FPar2"><title>Conflict of interest</title><p>The ON-TIME&#160;3 trial is funded by AstraZeneca and the Isala Academy. Dr. van &#8217;t Hof reports institutional fees and non-financial support from AstraZeneca as well as grants from Medtronic. A.H.&#160;Tavenier, R.S.&#160;Hermanides, J.P.&#160;Ottervanger, S.&#160;Rasoul, R.J.&#160;Slingerland, R.&#160;Tolsma, S.&#160;van Workum and E.&#160;Kedhi declare that they have no competing interests.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heestermans</surname><given-names>AA</given-names></name><name><surname>van Werkum</surname><given-names>JW</given-names></name><name><surname>Taubert</surname><given-names>D</given-names></name><etal/></person-group><article-title>Impaired bioavailability of clopidogrel in patients with a&#160;ST-segment elevation myocardial infarction</article-title><source>Thromb Res</source><year>2008</year><volume>122</volume><issue>6</issue><fpage>776</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2008.01.021</pub-id><pub-id pub-id-type="pmid">18455217</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#8217;Gara</surname><given-names>PT</given-names></name><name><surname>Kushner</surname><given-names>FG</given-names></name><name><surname>Ascheim</surname><given-names>DD</given-names></name><name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a&#160;report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title><source>Circulation</source><year>2013</year><volume>127</volume><issue>4</issue><fpage>e362</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1161/CIR.0b013e3182742c84</pub-id><pub-id pub-id-type="pmid">23247304</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibanez</surname><given-names>B</given-names></name><name><surname>James</surname><given-names>S</given-names></name><name><surname>Agewall</surname><given-names>S</given-names></name><etal/></person-group><article-title>2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)</article-title><source>Eur Heart J</source><year>2018</year><volume>39</volume><issue>2</issue><fpage>119</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx393</pub-id><pub-id pub-id-type="pmid">28886621</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>CP</given-names></name><name><surname>Mullins</surname><given-names>KV</given-names></name><name><surname>Sidhu</surname><given-names>SS</given-names></name><name><surname>Schulman</surname><given-names>SP</given-names></name><name><surname>McEvoy</surname><given-names>JW</given-names></name></person-group><article-title>The on- and off-target effects of morphine in acute coronary syndrome: a&#160;narrative review</article-title><source>Am Heart J</source><year>2016</year><volume>176</volume><fpage>114</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2016.04.004</pub-id><pub-id pub-id-type="pmid">27264228</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubica</surname><given-names>J</given-names></name><name><surname>Adamski</surname><given-names>P</given-names></name><name><surname>Ostrowska</surname><given-names>M</given-names></name><etal/></person-group><article-title>Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial</article-title><source>Eur Heart J</source><year>2016</year><volume>37</volume><issue>3</issue><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv547</pub-id><pub-id pub-id-type="pmid">26491112</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parodi</surname><given-names>G</given-names></name><name><surname>Bellandi</surname><given-names>B</given-names></name><name><surname>Xanthopoulou</surname><given-names>I</given-names></name><etal/></person-group><article-title>Morphine is associated with a&#160;delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention</article-title><source>Circ Cardiovasc Interv</source><year>2014</year><volume>8</volume><issue>1</issue><fpage>e001593</fpage><?supplied-pmid 25552565?><pub-id pub-id-type="pmid">25552565</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tantry</surname><given-names>US</given-names></name><name><surname>Bonello</surname><given-names>L</given-names></name><name><surname>Aradi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>62</volume><issue>24</issue><fpage>2261</fpage><lpage>2273</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2013.07.101</pub-id><pub-id pub-id-type="pmid">24076493</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonello</surname><given-names>L</given-names></name><name><surname>Pansieri</surname><given-names>M</given-names></name><name><surname>Mancini</surname><given-names>J</given-names></name><etal/></person-group><article-title>High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>58</volume><issue>5</issue><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2011.04.017</pub-id><pub-id pub-id-type="pmid">21777742</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McEvoy</surname><given-names>JW</given-names></name><name><surname>Ibrahim</surname><given-names>K</given-names></name><name><surname>Kickler</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: the PACIFY randomized clinical trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)</article-title><source>Circulation</source><year>2018</year><volume>137</volume><issue>3</issue><fpage>307</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.031678</pub-id><pub-id pub-id-type="pmid">29046319</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvain</surname><given-names>J</given-names></name><name><surname>Storey</surname><given-names>RF</given-names></name><name><surname>Cayla</surname><given-names>G</given-names></name><etal/></person-group><article-title>P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study</article-title><source>Thromb Haemost</source><year>2016</year><volume>116</volume><issue>2</issue><fpage>369</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1160/TH15-12-0944</pub-id><pub-id pub-id-type="pmid">27196998</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobl</surname><given-names>EL</given-names></name><name><surname>Stimpfl</surname><given-names>T</given-names></name><name><surname>Ebner</surname><given-names>J</given-names></name><etal/></person-group><article-title>Morphine decreases clopidogrel concentrations and effects: a&#160;randomized, double-blind, placebo-controlled trial</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>63</volume><issue>7</issue><fpage>630</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2013.10.068</pub-id><pub-id pub-id-type="pmid">24315907</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>TW</given-names></name><name><surname>Mumford</surname><given-names>AD</given-names></name><name><surname>Scott</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>A study of platelet inhibition, using a&#160;&#8216;point of care&#8217; platelet function test, following primary percutaneous coronary intervention for ST-elevation myocardial infarction [PINPOINT-PPCI</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><issue>12</issue><fpage>e0144984</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0144984</pub-id><pub-id pub-id-type="pmid">26672598</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellandi</surname><given-names>B</given-names></name><name><surname>Zocchi</surname><given-names>C</given-names></name><name><surname>Xanthopoulou</surname><given-names>I</given-names></name><etal/></person-group><article-title>Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI</article-title><source>Int J Cardiol</source><year>2016</year><volume>221</volume><fpage>567</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2016.06.204</pub-id><pub-id pub-id-type="pmid">27420579</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Waha</surname><given-names>S</given-names></name><name><surname>Eitel</surname><given-names>I</given-names></name><name><surname>Desch</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intravenous morphine administration and reperfusion success in ST-elevation myocardial infarction: insights from cardiac magnetic resonance imaging</article-title><source>Clin Res Cardiol</source><year>2015</year><volume>104</volume><issue>9</issue><fpage>727</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1007/s00392-015-0835-2</pub-id><pub-id pub-id-type="pmid">25725777</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meine</surname><given-names>TJ</given-names></name><name><surname>Roe</surname><given-names>MT</given-names></name><name><surname>Chen</surname><given-names>AY</given-names></name><etal/></person-group><article-title>Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative</article-title><source>Am Heart J</source><year>2005</year><volume>149</volume><issue>6</issue><fpage>1043</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2005.02.010</pub-id><pub-id pub-id-type="pmid">15976786</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puymirat</surname><given-names>E</given-names></name><name><surname>Lamhaut</surname><given-names>L</given-names></name><name><surname>Bonnet</surname><given-names>N</given-names></name><etal/></person-group><article-title>Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme</article-title><source>Eur Heart J</source><year>2016</year><volume>37</volume><issue>13</issue><fpage>1063</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv567</pub-id><pub-id pub-id-type="pmid">26578201</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parodi</surname><given-names>G</given-names></name><name><surname>Xanthopoulou</surname><given-names>I</given-names></name><name><surname>Bellandi</surname><given-names>B</given-names></name><etal/></person-group><article-title>Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study</article-title><source>J Am Coll Cardiol</source><year>2015</year><volume>65</volume><issue>5</issue><fpage>511</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2014.08.056</pub-id><pub-id pub-id-type="pmid">25660931</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niezgoda</surname><given-names>P</given-names></name><name><surname>Sikora</surname><given-names>J</given-names></name><name><surname>Baranska</surname><given-names>M</given-names></name><etal/></person-group><article-title>Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study</article-title><source>Thromb Haemost</source><year>2017</year><volume>117</volume><issue>4</issue><fpage>718</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1160/TH16-08-0670</pub-id><pub-id pub-id-type="pmid">28203684</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cutlip</surname><given-names>DE</given-names></name><name><surname>Nakazawa</surname><given-names>G</given-names></name><name><surname>Krucoff</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Autopsy validation study of the academic research consortium stent thrombosis definition</article-title><source>JACC Cardiovasc. Interv.</source><year>2011</year><volume>4</volume><issue>5</issue><fpage>554</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1016/j.jcin.2011.01.011</pub-id><pub-id pub-id-type="pmid">21596329</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Third universal definition of myocardial infarction</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><issue>20</issue><fpage>2551</fpage><lpage>2567</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehs184</pub-id><pub-id pub-id-type="pmid">22922414</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehran</surname><given-names>R</given-names></name><name><surname>Rao</surname><given-names>SV</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Standardized bleeding definitions for cardiovascular clinical trials: a&#160;consensus report from the Bleeding Academic Research Consortium</article-title><source>Circulation</source><year>2011</year><volume>123</volume><issue>23</issue><fpage>2736</fpage><lpage>2747</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.009449</pub-id><pub-id pub-id-type="pmid">21670242</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martini</surname><given-names>AK</given-names></name><name><surname>Rodriguez</surname><given-names>CM</given-names></name><name><surname>Cap</surname><given-names>AP</given-names></name><name><surname>Martini</surname><given-names>WZ</given-names></name><name><surname>Dubick</surname><given-names>MA</given-names></name></person-group><article-title>Acetaminophen and meloxicam inhibit platelet aggregation and coagulation in blood samples from humans</article-title><source>Blood Coagul Fibrinolysis</source><year>2014</year><volume>25</volume><issue>8</issue><fpage>831</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1097/MBC.0000000000000162</pub-id><pub-id pub-id-type="pmid">25004022</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munsterhjelm</surname><given-names>E</given-names></name><name><surname>Munsterhjelm</surname><given-names>NM</given-names></name><name><surname>Niemi</surname><given-names>TT</given-names></name><name><surname>Ylikorkala</surname><given-names>O</given-names></name><name><surname>Neuvonen</surname><given-names>PJ</given-names></name><name><surname>Rosenberg</surname><given-names>PH</given-names></name></person-group><article-title>Dose-dependent inhibition of platelet function by acetaminophen in healthy volunteers</article-title><source>Anesthesiology</source><year>2005</year><volume>103</volume><issue>4</issue><fpage>712</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1097/00000542-200510000-00009</pub-id><pub-id pub-id-type="pmid">16192763</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galliard-Grigioni</surname><given-names>KS</given-names></name><name><surname>Fehr</surname><given-names>M</given-names></name><name><surname>Reinhart</surname><given-names>WH</given-names></name></person-group><article-title>Influence of combinations of acetylsalicylic acid, acetaminophen, and diclofenac on platelet aggregation</article-title><source>Eur J Pharmacol</source><year>2008</year><volume>595(1-3)</volume><fpage>65</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2008.07.036</pub-id><pub-id pub-id-type="pmid">18700139</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>K</given-names></name><name><surname>Goli</surname><given-names>RR</given-names></name><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Resar</surname><given-names>JR</given-names></name><name><surname>Schulman</surname><given-names>SP</given-names></name><name><surname>McEvoy</surname><given-names>JW</given-names></name></person-group><article-title>Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: design, rationale, and sample characteristics of the PACIFY randomized trial. Contemp Clin</article-title><source>Trials</source><year>2018</year><volume>64</volume><fpage>8</fpage><lpage>12</lpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalescot</surname><given-names>G</given-names></name></person-group><article-title>van&#8217;t Hof AW, Lapostolle F, et&#160;al. Prehospital ticagrelor in ST-segment elevation myocardial infarction</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>11</issue><fpage>1016</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1407024</pub-id><pub-id pub-id-type="pmid">25175921</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Mahaffey</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Effect of platelet inhibition with cangrelor during PCI on ischemic events</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><issue>14</issue><fpage>1303</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1300815</pub-id><pub-id pub-id-type="pmid">23473369</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venetsanos</surname><given-names>D</given-names></name><name><surname>Sederholm Lawesson</surname><given-names>S</given-names></name><name><surname>Swahn</surname><given-names>E</given-names></name><name><surname>Alfredsson</surname><given-names>J</given-names></name></person-group><article-title>Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: the inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a&#160;randomised controlled trial</article-title><source>Thromb Res</source><year>2017</year><volume>149</volume><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2016.10.013</pub-id><pub-id pub-id-type="pmid">27773347</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>D</given-names></name><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name></person-group><article-title>Risk of cardiovascular events associated with selective COX-2 inhibitors</article-title><source>JAMA</source><year>2001</year><volume>286</volume><issue>8</issue><fpage>954</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1001/jama.286.8.954</pub-id><pub-id pub-id-type="pmid">11509060</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantais</surname><given-names>A</given-names></name><name><surname>Schnell</surname><given-names>D</given-names></name><name><surname>Vincent</surname><given-names>F</given-names></name><etal/></person-group><article-title>Acetaminophen-induced changes in systemic blood pressure in critically ill patients: results of a&#160;multicenter cohort study</article-title><source>Crit Care Med</source><year>2016</year><volume>44</volume><issue>12</issue><fpage>2192</fpage><lpage>2198</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000001954</pub-id><pub-id pub-id-type="pmid">27414476</pub-id></element-citation></ref></ref-list></back></article>